Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1792963

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1792963

Infantile Spasm Therapeutics

PUBLISHED:
PAGES: 377 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Infantile Spasm Therapeutics Market to Reach US$3.8 Billion by 2030

The global market for Infantile Spasm Therapeutics estimated at US$3.2 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Anticonvulsants, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Corticosteroids segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$878.8 Million While China is Forecast to Grow at 5.4% CAGR

The Infantile Spasm Therapeutics market in the U.S. is estimated at US$878.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$743.7 Million by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Infantile Spasm Therapeutics Market - Key Trends & Drivers Summarized

Why Is Infantile Spasm Emerging as an Urgent Therapeutic Priority?

Infantile spasm, also known clinically as West syndrome, has moved to the forefront of pediatric neurology because of its devastating developmental consequences, its complex neurophysiology, and its increasing visibility through improved diagnostic vigilance. The disorder typically strikes within the first year of life, presenting with clusters of brief but explosive axial contractions that are easily mistaken for benign startle reflexes, gastroesophageal reflux posturing, or simple myoclonic jerks until developmental arrest or regression becomes undeniable. Neurophysiologists now recognize a distinctly chaotic electroencephalographic signature called hypsarrhythmia, and widespread deployment of video EEG monitoring units in neonatal intensive care settings is driving earlier detection. Epidemiological data suggest an incidence of roughly two to four cases per ten thousand live births, yet prevalence is amplified in regions with high rates of perinatal hypoxic-ischemic injury, tuberous sclerosis complex, or prenatal infections-all factors that remain stubbornly common in many low-- and middle-income countries. Untreated or suboptimally managed spasms progress rapidly to cognitive impairment, refractory epilepsy, and autism-spectrum behaviors, making prompt therapeutic intervention essential for neurodevelopmental preservation. Caregiver advocacy groups and social media communities have amplified the voices of parents who describe sudden loss of eye contact, developmental plateau, and catastrophic EEG findings, pressing health systems to shorten referral times from primary care to pediatric epilepsy specialists. Consequently, clinicians now face both ethical and logistical imperatives to initiate disease-modifying therapy within days rather than months of symptom onset, reshaping treatment paradigms and elevating infantile spasm therapeutics to a public health priority.

Can Scientific Innovation Transform Treatment Outcomes Beyond Traditional Hormonal Protocols?

Contemporary management of infantile spasm is evolving well beyond legacy protocols centered on adrenocorticotropic hormone and oral corticosteroids, both of which can terminate spasms but carry risks of hypertension, immunosuppression, and reversible brain atrophy. Precision pharmacology has introduced vigabatrin, a selective irreversible inhibitor of gamma-aminobutyric-acid transaminase, as the first-line option for spasms associated with tuberous sclerosis complex and as a key second-line therapy in cryptogenic cases. Ongoing phase III trials are evaluating next-generation GABA-ergic analogues that maintain seizure suppression while minimizing irreversible visual field defects, a notorious complication seen with high cumulative vigabatrin exposure. Investigators are also assessing ganaxolone, a synthetic neurosteroid modulating synaptic and extrasynaptic GABA-A receptors, which has shown promising open-label efficacy when combined with prednisolone. Elsewhere, mTOR pathway inhibitors such as everolimus are being repurposed from oncology to address the upstream dysregulation underlying tuberous sclerosis-related epileptogenesis, offering a disease-targeted alternative rather than purely symptomatic control. Interest in gene-specific therapies is mounting, with antisense oligonucleotides being explored for CDKL5 deficiency and STXBP1 encephalopathy, both high-risk genotypes for early infantile spasms. Neuromodulation strategies are advancing as well: responsive neurostimulation for infants remains experimental, but deep brain stimulation targeting the centromedian thalamic nucleus has entered compassionate-use programs. Nutritional therapies are also under rigorous scrutiny; modified ketogenic protocols with precisely titrated medium-chain triglycerides are demonstrating spasm reduction while mitigating the metabolic burden of classic ketogenic diets. Collectively, these scientific advances are creating a multidimensional therapeutic landscape aimed not only at terminating spasms but also at altering the underlying neurodevelopmental trajectory, heralding a new era of precision and personalization in infantile spasm care.

How Do Regulatory, Economic, and Caregiver Factors Influence Therapy Adoption and Accessibility?

The pathway from laboratory breakthrough to bedside impact in infantile spasm therapeutics is strongly mediated by regulatory frameworks, payer decisions, and the lived realities of caregivers. Designation of infantile spasm treatments as orphan drugs in the United States, Europe, and Japan confers market exclusivity, tax incentives, and abbreviated review timelines, accelerating entry of innovative agents yet often resulting in premium launch prices. Cost-utility analyses reveal that early seizure control yields long-term savings by reducing intensive developmental therapies and special-education services, prompting some national health authorities to reimburse expensive biologics when robust real-world evidence supports durable cognitive gains. Still, disparities persist: in many low-resource settings, availability of ACTH remains limited to compounded formulations with variable bioactivity, while vigabatrin tablets are frequently out of stock or unaffordable without humanitarian procurement channels. Tele-neurology platforms are beginning to bridge geographic gaps by connecting regional hospitals to tertiary epilepsy centers for rapid EEG interpretation and treatment initiation recommendations, although broadband penetration and clinician bandwidth remain limiting factors. Caregivers play an outsized role in treatment adherence, juggling complex steroid taper schedules, vigilant blood-pressure monitoring, and monthly ophthalmologic exams. Educational toolkits in multiple languages, text-message reminder systems, and peer-mentor programs have proven effective in sustaining adherence during the critical six-month consolidation window that follows therapy onset. Ethics committees and patient-advocacy councils influence trial design by demanding inclusion of neurodevelopmental endpoints alongside seizure metrics, ensuring that developmental quality-of-life considerations guide regulatory approvals. Collectively, these non-clinical forces shape market penetration and therapeutic equity, underscoring that breakthrough science must be paired with policy innovation and caregiver engagement to achieve population-level impact.

What Is Driving the Accelerated Growth of the Infantile Spasm Therapeutics Market?

The growth in the infantile spasm therapeutics market is driven by several factors rooted in heightened diagnostic acuity, expanding genetic insights, progressive reimbursement policies, and a robust pipeline of targeted therapies that promise superior efficacy with manageable safety profiles. First, widespread adoption of high-resolution video EEG monitoring in newborn nurseries and emergency departments is identifying spasms earlier, enlarging the treatable population and emphasizing the value of rapid-acting agents. Second, next-generation sequencing panels are unmasking pathogenic variants that not only clarify prognosis but also point toward molecularly tailored interventions, accelerating investment in gene-specific therapeutics and companion diagnostics. Third, orphan-drug incentives and pediatric priority review vouchers are lowering commercial risk, encouraging biotech firms to pursue small-population indications with high unmet need. Fourth, real-world data from national epilepsy registries are providing compelling evidence that early intervention improves cognitive trajectories, prompting insurers and national health services to reimburse premium therapies and even fund home-based steroid administration programs. Fifth, strategic collaborations between pharmaceutical companies and academic epilepsy centers are streamlining phase II proof-of-concept studies through adaptive trial designs, shortening development timelines without compromising rigor. Sixth, the proliferation of caregiver advocacy networks is boosting public awareness, driving fundraising for research, and catalyzing policy reforms that facilitate medication importation and compassionate-use access. Seventh, emerging digital therapeutics that integrate seizure-detection wearables and AI-driven dosing algorithms are poised to complement pharmacologic regimens, opening ancillary revenue streams and reinforcing the overall market ecosystem. These interlocking drivers are collectively transforming infantile spasm therapeutics from a niche subspecialty concern into a vibrant, fast-growing domain of pediatric neuroscience innovation poised to deliver meaningful improvements in survival, cognition, and quality of life for affected infants worldwide.

SCOPE OF STUDY:

The report analyzes the Infantile Spasm Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapeutic Class (Anticonvulsants, Corticosteroids, Other Therapeutic Classes); Drug Type (Vigabatrin, Adrenocorticotropic Hormone, Other Drug Types); Dosage (Solid Dosage, Liquid Dosage)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • Amneal Pharmaceuticals
  • ANI Pharmaceuticals
  • Biocodex SA
  • Boehringer Ingelheim
  • Catalyst Pharmaceuticals
  • Cipla Limited
  • Currax Pharmaceuticals LLC
  • Dr. Reddy's Laboratories Ltd.
  • GW Pharmaceuticals (Jazz Pharma)
  • Hikma Pharmaceuticals Plc
  • Ionis Pharmaceuticals
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • Marinus Pharmaceuticals
  • Medexus Pharmaceuticals Inc.
  • Mylan (Viatris Inc.)
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP37188

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Infantile Spasm Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Diagnosis Rates and Early Intervention Efforts Throw the Spotlight on Infantile Spasm Therapeutics as a Critical Segment in Pediatric Neurology
    • Increasing Awareness Among Pediatricians and Neurologists Propels Demand for Timely and Evidence-Based Treatment Approaches
    • Here's the Story: Clinical Guidelines Emphasizing Early Treatment Strengthen the Business Case for First-Line Therapeutics
    • Advances in Neuroimaging and EEG Technologies Drive Earlier and More Accurate Identification of Infantile Spasms
    • Growing Pipeline of ACTH Analogs, Steroids, and Antiepileptic Drugs Supports Innovation in Drug Formulations and Dosing Regimens
    • Here's How Research in Genetic and Metabolic Causes of Infantile Spasms Is Opening Doors to Targeted Therapies
    • Rising Focus on Neurodevelopmental Outcomes Fuels Demand for Fast-Acting and Tolerable Therapeutic Options
    • Global Expansion of Pediatric Specialty Clinics Enhances Access to Infantile Spasm Treatment in Urban and Semi-Urban Areas
    • Growth in Specialty Pharmaceuticals and Orphan Drug Designation Accelerates R&D and Market Entry of Novel Therapeutics
    • Emergence of Precision Medicine and Genetic Screening Fuels Long-Term Potential for Personalized Infantile Spasm Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Infantile Spasm Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Infantile Spasm Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Infantile Spasm Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Therapeutic Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Vigabatrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Vigabatrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Vigabatrin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Adrenocorticotropic Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Adrenocorticotropic Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Adrenocorticotropic Hormone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Solid Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Solid Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Solid Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Liquid Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Liquid Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Liquid Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • JAPAN
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • CHINA
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: China 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • EUROPE
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Infantile Spasm Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Infantile Spasm Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • FRANCE
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: France 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • GERMANY
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Spain 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Russia 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Australia 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • INDIA
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: India 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: South Korea 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Infantile Spasm Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Argentina 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Brazil 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Mexico 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Infantile Spasm Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Iran 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Israel 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: UAE 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • AFRICA
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Africa 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!